Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PTC THERAPEUTICS, INC. shareholders approved Election of four Class I directors at the 2023-06-06 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
The stockholders of the Company elected four Class I directors, each to hold office until the Company's 2026 annual meeting of stockholders or until his or her successor has been duly elected and qualified, as follows: Director For Withheld Broker Non-Votes William F. Bell, Jr. 63,215,577 3,588,990 2,986,852 Matthew B. Klein, M.D., M.S., F.A.C.S. 66,478,887 325,680 2,986,852 Stephanie S. Okey, M.S. 63,816,731 2,987,836 2,986,852 Jerome B. Zeldis, M.D., Ph.D. 58,377,983 8,426,584 2,986,852
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PTC THERAPEUTICS, INC. shareholders approved Non-binding advisory proposal on named executive officer compensation at the 2023-06-06 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
The non-binding advisory proposal on named executive officer compensation was approved by the Company's stockholders with 65,318,123 votes "For,” 1,464,756 votes “Against,” 21,688 votes “Abstained,” and 2,986,852 broker non-votes.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PTC THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-06 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified by the Company's stockholders with 69,370,823 votes "For,” 406,974 votes “Against,” and 13,622 votes “Abstained.”
View on SEC.gov